Top Low Price Stocks To Buy Right Now

Top Low Price Stocks To Buy Right Now: Vical Incorporated(VICL)

Vical Incorporated engages in the research and development of biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its products include Allovectin, a Phase III clinical trial product to treat metastatic melanoma; CyMVectin prophylactic vaccine for cytomegalovirus, which completed preclinical trial to prevent infection before pregnancy to preclude fetal transmission; and therapeutic and prophylactic vaccines for herpes simplex type 2 virus, which is under preclinical trial to prevent and protect against recurring flare-ups, reduce viral shedding ,and transmission. The company, through corporate collaborations, develops TransVax, which is in Phase III clinical trials to protect against CMV infection after stem cell transplants, as well as in Phase II clinical trial to protect against CMV infection after solid organ transplants; Collategene, an angiogenic therapy enc oding hepatocyte growth factor that is in Phase III clinical trials to induce local growth of blood vessels to restore blood flow to limbs affected by critical limb ischemia; Apex-IHN prophylactic vaccine for infectious hematopoietic necrosis virus for the prevention of infection and disease in farm-raised salmon when exposed to infected wild salmon ; and ONCEPT therapeutic cancer vaccine encoding human tyrosinase for the treatment to increase survival time of dogs with oral melanoma. Vical Incorporated, through government collaboration, develops Prophylactic and/or therapeutic HIV vaccine, a Phase IIb clinical trial product to prevent/treat infection, disease, and/or viral shedding; and Tetravalent dengue vaccine, a Phase I clinical trial product to prevent dengue disease caused by all 4 dengue serotypes. The company was founded in 1987 and is based in San Diego, California! .

Advisors' Opinion:

• [By Rich Bieglmeier]

  [Related -Vical (VICL) Licenses Vaxfectin Adjuvant For Use In Malaria Vaccines To Cyvax]

  Vical researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases.

• [By Roberto Pedone]

  Another stock that's starting to trend within range of triggering a major breakout trade is Vical (VICL), which engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. This stock has been hit hard by the sellers over the last six months, with shares off sharply by 65%.

  If you look at the chart for Vical, you'll notice that this stock has been trending sideways and consolidating over the last two months, with shares moving between $1.01 on the downside and $1.35 on the upside. Shares of VICL have started to uptrend over the last few weeks, with shares moving higher from its low of $1.01 to its recent high of $1.35 a share. During that move, shares of VICL have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now taken shares of VICL back above its 50-day moving average of $1.16 share and it's quickly pushing the stock within range of triggering a major breakout trade.

  Traders should now look for long-biased trades in VICL if it manages to break out above some near-term overhead resistance at $1.35 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.17 million shares. If that breakout hits soon, then VICL will set up to re-test or possibly take out its next major overhead resistance level at $1.53 a share to its gap-down day high of $1.61 a share. Any high-volume move above those levels will then give ! VICL a ch! ance to re-fill some of its previous gap-down-day zone from last August that started at $3.70 a share.

  Traders can look to buy VICL off any weakness to anticipate that breakout and simply use a stop that sits just below its 50-day moving average at $1.20 a share or near more support at $1.10 a share. One can also buy VICL off strength once it starts to cle

source from Top Stocks Blog:http://www.topstocksblog.com/top-low-price-stocks-to-buy-right-now.html